J Korean Soc Radiol.  2023 Nov;84(6):1244-1256. 10.3348/jksr.2023.0060.

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

• Jang JS
• Lee AJ
• Park KJ
• Kim KW
• Park HJ

• KMID: 2548580
• DOI: http://doi.org/10.3348/jksr.2023.0060

Abstract

In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response. Castration-resistant prostate cancer refers to the state wherein the cancer continues to progress despite a significant reduction of the sex hormone level and is associated with frequent distant metastasis. The Prostate Cancer Working Group 3 (PCWG3) released guidelines that aimed to standardize the assessment of treatment effects in castration-resistant prostate cancer using bone scintigraphy. However, these guidelines can be challenging to comprehend and implement in practical settings. The purpose of this review was to provide an overview of a specific image acquisition method and treatment re-sponse assessment for bone scintigraphy-based evaluation of bone lesions in metastatic castrationresistant prostate cancer, in accordance with the PCWG3 guidelines.

Keyword

Prostate; Cancer; Bonescan; PCWG3